knowledge -WSS

knowledge

author：hotspot 2025-10-02 21:05:11 - browse：648

Bristol Myers Squibb sign — Courtesy Bristol Myers Squibb

Bristol Myers Squibb said that it would purchase Mirati Therapeutics, maker of the cancer drug Krazati, for $4.8 billion in cash in a deal that shows the continued interest of large pharmaceutical firms in relatively small “bolt-on” acquisitions.

Bristol said that it would pay $58.00 per share for Mirati, and would hold another $12.00 per share, or a total of $1 billion, to be paid if one of two different applications for an additional use for Krazati is approved within seven years after the merger closes.

Chris Boerner, Bristol’s chief operating officer and CEO-elect, said in a statement that Mirati had several cancer drugs in development that could deliver sales in the latter half of the decade and beyond, when investors worry that Bristol will need new products to sustain its growth.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： DIEP, the 'gold standard' of breast reconstruction, is under threat
Next article： H.R. 3 is the wrong path to lower drug costs

explore

entertainment

WSS

Bright Health sells Medicare Advantage business to Molina

CDC recommends RSV monoclonal antibody for infants

Flint parents haunted by uncertainty, fears of lead poisoning

ChatGPT in medicine: STAT answers readers' burning questions

Physicians aren't 'burning out.' They're suffering from moral injury

How one medical school became remarkably diverse

entertainment

knowledge

hotspot

Wildfire smoke exposes gaps in outdoor worker protections

How to ethically and practically extend health care to all

Moonlake's readout produced a cash windfall. Risks remain

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

Malaria cases in Florida and Texas: Here’s what you need to know

Personalized medicine goes far beyond genetics

Medicare proposal to cover medical devices draws a mixed reaction

State Dept. review finds Biden bears some blame for Afghanistan failures

In age of alternative facts, a scholarly course on calling out crap

作为一名理智的商人，吴多早已把自己的主要经销业务由乐视电视变更为小米手机、小米电视。

explore

Virginia high school admissions case could be legal follow

FDA approves Sage Therapeutics’ rapid

Flint parents haunted by uncertainty, fears of lead poisoning

Personalized medicine goes far beyond genetics

Medicare proposal to cover medical devices draws a mixed reaction

23andMe had bad news about my health. I wish a person had delivered it

focus

explore

entertainment

focus